Microfluidic ELISA SARS-CoV-2 Antigen Test
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current SARS-CoV-2 testing capabilities are limited by labor-intensive laboratory-based RT-PCR tests and existing rapid tests, which lack sensitivity and throughput, necessitating the development of rapid and accurate point-of-care diagnostic tests that can be deployed in remote locations without centralized laboratories.
Innovation Solution
A novel ELISA-based assay using optimized antibodies and a microfluidic platform with pneumatic pistons and valves for improved sensitivity and throughput, capable of detecting SARS-CoV-2 antigens with quantitative results, including viral RNA copies per milliliter, and N protein levels, in a compact, automated format.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If rapid antigen tests using lateral flow assay technology are used, then the test can be performed rapidly and portably, but the sensitivity is poor especially in patients with lower viral concentrations
Solution Approach 1:
The assay divides the detection process into multiple discrete steps within the microfluidic channel: sample introduction, antigen capture by immobilized antibodies, incubation, detection antibody binding, and signal measurement. This segmentation allows each step to be optimized independently, achieving both rapid processing and high sensitivity through controlled sequential reactions rather than simultaneous mixing.
Solution Approach 2:
The invention transitions from the lateral flow two-dimensional migration approach to a microfluidic three-dimensional controlled environment. The microfluidic channel provides precise spatial control over reagent mixing, incubation, and detection, enabling enhanced antigen-antibody interactions through optimized contact geometry and flow dynamics that improve sensitivity while maintaining rapid processing.
2Measurement precision
If rapid molecular tests that amplify and measure viral RNA are used, then the sensitivity is improved, but the throughput is low with only a few samples per hour
Solution Approach 1:
The assay merges the high sensitivity of molecular tests with the rapid processing of antigen tests by combining ELISA-based antigen detection with microfluidic automation. This integration achieves sensitivity comparable to RT-PCR while enabling batch processing of multiple samples through the automated microfluidic platform, thereby increasing throughput significantly compared to manual molecular methods.
Solution Approach 2:
The invention replaces the complex mechanical amplification steps of RT-PCR with an automated microfluidic ELISA system. The microfluidic platform uses programmed flow control to automate sample processing, reagent delivery, and detection, eliminating the need for manual pipetting and thermal cycling while maintaining sensitivity through optimized antibody-antigen interactions.
3Measurement precision
If laboratory based RT-PCR tests are used, then accurate detection is achieved, but the tests are labor intensive and require specialized equipment and centralized laboratories
Solution Approach 1:
The assay extracts the essential detection function from the complex RT-PCR system by directly detecting SARS-CoV-2 antigens without requiring RNA extraction, reverse transcription, or amplification steps. This extraction of the core detection capability enables accurate diagnosis using a simplified platform that does not require specialized laboratory equipment or centralized facilities.
Solution Approach 2:
The microfluidic ELISA system performs self-service automation, where the device automatically handles sample processing, reagent mixing, incubation, and detection without manual intervention. The integrated microfluidic channel system autonomously controls fluid flow and reaction conditions, eliminating the need for trained personnel and specialized equipment while maintaining detection accuracy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The assay provides superior sensitivity and precision compared to existing antigen tests, increased throughput compared to molecular tests, and is the first to report viral concentrations, enabling effective pandemic control and remote testing without the need for centralized labs.
Implementation Method 1
combining the fluid sample with an immobilized capture antibody that binds SARS-CoV-2 peptide within the microfluidic channel
Implementation Method 2
A detection antibody is then combined with and will bind to the SARS-CoV-2 peptide 'captured' within the channel
Implementation Method 3
the samples and reagents are directed by pneumatic pistons and valves through these channels
Data Source
AI summary
Aspects of the present disclosure relate to methods and systems designed to utilize antibodies and viral inactivating/lysis agents to detect SARS-CoV-2 on a microfluidic channel-based platform, for example in samples obtained from nasal swabs taken from infected individuals. The rapid and accurate point of care COVID-19 diagnostic tests that are disclosed herein can transform medical professional's testing capabilities, and in this way improve the ability to control the COVID-19 pandemic.